BACKGROUND: Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known. METHODS: We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis. RESULTS: Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline (P = .94 ). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (P = .034), renal failure at baseline (P = .016), and fungemia (P = .003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P = .007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P = .349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02-20.80; P = .047) and fungemia (OR, 10.66; 95% CI, 2.08-54.55; P = .004 ) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02-0.57; P = .008). CONCLUSIONS: Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients.
BACKGROUND: Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known. METHODS: We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis. RESULTS: Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline (P = .94 ). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (P = .034), renal failure at baseline (P = .016), and fungemia (P = .003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P = .007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P = .349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02-20.80; P = .047) and fungemia (OR, 10.66; 95% CI, 2.08-54.55; P = .004 ) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02-0.57; P = .008). CONCLUSIONS:Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients.
Authors: Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison Journal: Lancet Date: 2004-05-29 Impact factor: 79.321
Authors: A C Leenders; P Reiss; P Portegies; K Clezy; W C Hop; J Hoy; J C Borleffs; T Allworth; R H Kauffmann; P Jones; F P Kroon; H A Verbrugh; S de Marie Journal: AIDS Date: 1997-10 Impact factor: 4.177
Authors: Jane P Barrett; Katerina A Vardulaki; Christopher Conlon; Jonathan Cooke; Pascual Daza-Ramirez; E Glyn V Evans; Peter M Hawkey; Raoul Herbrecht; David I Marks; Jose M Moraleda; Gilbert R Park; Stephen J Senn; Claudio Viscoli Journal: Clin Ther Date: 2003-05 Impact factor: 3.393
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Ryosuke Osawa; Barbara D Alexander; Olivier Lortholary; Françoise Dromer; Graeme N Forrest; G Marshall Lyon; Jyoti Somani; Krishan L Gupta; Ramon Del Busto; Timothy L Pruett; Costi D Sifri; Ajit P Limaye; George T John; Goran B Klintmalm; Kenneth Pursell; Valentina Stosor; Michele I Morris; Lorraine A Dowdy; Patricia Muñoz; Andre C Kalil; Julia Garcia-Diaz; Susan Orloff; Andrew A House; Sally Houston; Dannah Wray; Shirish Huprikar; Leonard B Johnson; Atul Humar; Raymund R Razonable; Robert A Fisher; Shahid Husain; Marilyn M Wagener; Nina Singh Journal: Transplantation Date: 2010-01-15 Impact factor: 4.939
Authors: Emily W Bratton; Nada El Husseini; Cody A Chastain; Michael S Lee; Charles Poole; Til Stürmer; Jonathan J Juliano; David J Weber; John R Perfect Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Lucy O'Connor; Joanne Livermore; Andrew D Sharp; Joanne Goodwin; Lea Gregson; Susan J Howard; Timothy W Felton; Julie A Schwartz; Michael N Neely; Thomas S Harrison; John R Perfect; William W Hope Journal: J Infect Dis Date: 2013-04-18 Impact factor: 5.226
Authors: Rebecca S Campbell; Paresh Chaudhari; Harlen D Hays; Robert J Taylor; Brian H Nathanson; Samuel A Bozzette; David L Horn Journal: Clinicoecon Outcomes Res Date: 2013-10-24